Lv4
410 积分 2025-05-23 加入
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis
3小时前
待确认
Radioimmunotherapy for lung and head and neck cancers: A comparative review of clinical trial results and sequencing strategies
3小时前
已完结
Hyperbaric oxygen therapy for chronic radiotherapy‐related adverse effects: A clinically focused review
4小时前
已完结
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
26天前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
26天前
已完结
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
26天前
已完结
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
26天前
已完结
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
26天前
已完结
Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis
26天前
已完结
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
26天前
已完结
皖公网安备34019202002308
